This website is intended for healthcare professionals only

Changes to licensed indications

The information in the medicines tracker is based on the Regional Drug and Therapeutics Centre (RDTC) horizon scanning reports, which are intended to inform NHS healthcare professionals about new products available through the NHS and significant changes to current product licences.

MGP is not responsible for the information provided by the RDTC horizon scanning reports. Readers are advised to refer to the relevant summary of product characteristics.

To view the original documents in full, visit the Regional Drug and Therapeutics Centre website at:

Click here to view new products

Date Generic Brand Additional Information
May 2017 Dabrafenib Tafinlar®▼ View
May 2017 Trametinib Mekinist®▼ View
May 2017 Imatinib generic View
May 2017 Budesonide/formoterol Duoresp Spiromax® View
May 2017 Emtricitabine/tenofovir disoproxil Truvada® View
Apr 2017 Natalizumab Tysabri®▼ View
Apr 2017 Triptorelin Decapeptyl® SR View
Apr 2017 Imatinib generic View
Apr 2017 Dolutegravir Tivicay®▼ View
Apr 2017 Canakinumab Ilaris®▼ View
Mar 2017 Rosuvastatin Crestor® View
Mar 2017 Metformin/linagliptin Jentadueto® View
Mar 2017 Quetiapine fumarate Atrolak XL® View
Mar 2017 Fluticasone propionate, salmeterol xinafoate AirFluSal Forspiro® View
Mar 2017 Etanercept Benepali® View
Mar 2017 Linagliptin Trajenta® View
Mar 2017 5-aminolevulinic acid hydrochloride Ameluz® View
Mar 2017 Imatinib generic View
Mar 2017 Pembrolizumab Keytruda®▼ View
Feb 2017 Interferon alfa-2a Roferon-A® View